Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2017

Open Access 01-12-2017 | Research

Discriminative ability of quality of life measures in multiple sclerosis

Authors: Kirsten M. Fiest, Jamie Greenfield, Luanne M. Metz, Scott B. Patten, Nathalie Jetté, Ruth Ann Marrie

Published in: Health and Quality of Life Outcomes | Issue 1/2017

Login to get access

Abstract

Background

Though many people with multiple sclerosis (MS) have comorbidities, the use of generic and disease-specific health related quality of life (HRQOL) scales to discriminate the effects of comorbidity has not been established. The utility of these scales to discriminate differences between persons with varying levels of disability is also unknown.

Methods

Using online questionnaires, a convenience sample of Albertans with MS was recruited between July 2011 and March 2013. Participants completed demographic questions, a validated comorbidity questionnaire, a self-reported disability scale, and the following HRQOL scales: the Short Form (SF)-36, SF-6D, Health Utilities Index-Mark III (HUI-III), and Multiple Sclerosis Quality of Life-54 (MSQOL-54). The ability of each HRQOL scale to distinguish between comorbidity groups was assessed using a one-way analysis of covariance, adjusting for age, sex, disease course, and disability level.

Results

Five hundred sixty three participants completed all relevant questionnaires. All HRQOL measures distinguished between persons with or without depression, while none were able to distinguish between participants with or without hypertension, thyroid disease, irritable bowel syndrome, or osteoporosis. The SF-36 physical scale, SF-6D, HUI-III, and MSQOL-54 physical scales were able to distinguish between all disability groups, though the HUI-III was better able to distinguish between individuals with moderate versus severe disability.

Conclusions

Disease-specific measures would discriminate better between those with and without comorbidities than generic-specific measures and the HUI-III would discriminate best between persons with differing severities of disability. Generic or disease-specific measures may be useful in future studies examining the effects of comorbidity in MS and the effects of treatment of comorbidities in MS.
Appendix
Available only for authorised users
Literature
1.
Marrie RA, Cohen J, Stuve O, Trojano M, Sorensen PS, Reingold S, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler. 2015;21(3):263–81.CrossRefPubMedPubMedCentral
2.
Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. 2008;14(8):1091–8.CrossRefPubMed
3.
Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009;72(2):117–24.CrossRefPubMedPubMedCentral
4.
Weinstock-Guttman B, Zivadinov R, Mahfooz N, Carl E, Drake A, Schneider J, et al. Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation. 2011;8:127.CrossRefPubMedPubMedCentral
5.
Turpin KV, Carroll LJ, Cassidy JD, Hader WJ. Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs. Mult Scler. 2007;13(8):1038–45.CrossRefPubMed
6.
Warren S, Turpin KV, Warren KG. Health-related quality of life in MS: issues and interventions. Can J Neurol Sci. 2009;36(5):540–1.CrossRefPubMed
7.
Berrigan L, Fisk J, Patten S, Tremlett H, Wolfson C, Warren S, et al. Health-related quality of life in multiple sclerosis: direct and indirect effects of comorbidity. Neurology. 2016;86(15):1417–24.
8.
Benedict RH, Wahlig E, Bakshi R, Fishman I, Munschauer F, Zivadinov R, et al. Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci. 2005;231(1–2):29–34.CrossRefPubMed
9.
Nortvedt MW, Riise T, Myhr KM, Nyland HI. Quality of life in multiple sclerosis: measuring the disease effects more broadly. Neurology. 1999;53(5):1098–103.CrossRefPubMed
10.
Kobelt G, Berg J, Lindgren P, Fredrikson S, Jonsson B. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2006;77(8):918–26.CrossRefPubMedPubMedCentral
11.
Motl RW, Gosney JL. Effect of exercise training on quality of life in multiple sclerosis: a meta-analysis. Mult Scler. 2008;14(1):129–35.CrossRefPubMed
12.
Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther. 2009;26(12):1043–57.CrossRefPubMed
13.
Grima DT, Torrance GW, Francis G, Rice G, Rosner AJ, Lafortune L. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler. 2000;6(2):91–8.CrossRefPubMed
14.
Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry. 2005;76(1):58–63.CrossRefPubMedPubMedCentral
15.
Hohol MJ, Orav EJ, Weiner HL. Disease steps in multiple sclerosis: a simple approach to evaluate disease progression. Neurology. 1995;45(2):251–5.CrossRefPubMed
16.
Learmonth YC, Motl RW, Sandroff BM, Pula JH, Cadavid D. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol. 2013;13:37.CrossRefPubMedPubMedCentral
17.
Wiebe S, Guyatt G, Weaver B, Matijevic S, Sidwell C. Comparative responsiveness of generic and specific quality-of-life instruments. J Clin Epidemiol. 2003;56(1):52–60.CrossRefPubMed
18.
Horsman J, Furlong W, Feeny D, Torrance G. The health utilities index (HUI): concepts, measurement properties and applications. Health Qual Life Outcomes. 2003;1:54.CrossRefPubMedPubMedCentral
19.
Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res. 1995;4(3):187–206.CrossRefPubMed
20.
Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.CrossRefPubMed
21.
Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271–92.CrossRefPubMed
22.
Dallmeijer AJ, de Groot V, Roorda LD, Schepers VP, Lindeman E, van den Berg LH, et al. Cross-diagnostic validity of the SF-36 physical functioning scale in patients with stroke, multiple sclerosis and amyotrophic lateral sclerosis: a study using Rasch analysis. J Rehabil Med. 2007;39(2):163–9.CrossRefPubMed
23.
Riazi A, Hobart JC, Lamping DL, Fitzpatrick R, Thompson AJ. Evidence-based measurement in multiple sclerosis: the psychometric properties of the physical and psychological dimensions of three quality of life rating scales. Mult Scler. 2003;9(4):411–9.CrossRefPubMed
24.
Kuspinar A, Mayo NE. A review of the psychometric properties of generic utility measures in multiple sclerosis. PharmacoEconomics. 2014;32(8):759–73.CrossRefPubMed
25.
Freeman JA, Hobart JC, Thompson AJ. Does adding MS-specific items to a generic measure (the SF-36) improve measurement? Neurology. 2001;57(1):68–74.CrossRefPubMed
26.
Moore F, Vickrey B, Fortin K, Lee L. Two multiple sclerosis quality-of-life measures: comparison in a National Sample. Can J Neurol Sci. 2015;42(1):55–63.CrossRefPubMed
27.
Horton M, Rudick RA, Hara-Cleaver C, Marrie RA. Validation of a self-report comorbidity questionnaire for multiple sclerosis. Neuroepidemiology. 2010;35(2):83–90.CrossRefPubMed
28.
Swinscow TDV, 11. Correlation and regression, in Statistics at Square One. London: BMJ Publishing Group. 1997.
29.
Luo N, Wang P, AZ F, Johnson JA, Coons SJ. Prefderence-based SF-6D scores derived from the SF-36 and SF-12 have different discriminative power in a population health survey. Med Care. 2012;50(7):627–32.CrossRefPubMed
30.
Fiest KM, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, et al. Comorbidity is associated with pain-related activity limitations in multiple sclerosis. Mult Scler Relat Disord. 2015;4(5):470–6.CrossRefPubMed
31.
Buhse M, Banker WM, Clement LM. Factors associated with health-related quality of life among older people with multiple sclerosis. Int J MS Care. 2014;16(1):10–9.CrossRefPubMedPubMedCentral
32.
Ontaneda D, Fox RJ, Chataway J. Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. Lancet Neurol. 2015;14(2):208–23.CrossRefPubMedPubMedCentral
33.
Metz LM, Greenfield J, Marrie R, Jette N, Blevens G, Svenson L, et al. Medical tourism for CCSVI procedures in people with MS: an observational study. Can J Neurol Sci. 2016;43(3):360–7.CrossRefPubMed
Metadata
Title
Discriminative ability of quality of life measures in multiple sclerosis
Authors
Kirsten M. Fiest
Jamie Greenfield
Luanne M. Metz
Scott B. Patten
Nathalie Jetté
Ruth Ann Marrie
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2017
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-017-0828-0

Other articles of this Issue 1/2017

Health and Quality of Life Outcomes 1/2017 Go to the issue

Research

Developing a questionnaire to determine the impact of self-management in diabetes: giving people with diabetes a voice

Research

Domains of quality of life freely expressed by cancer patients and their caregivers: contribution of the SEIQoL

Research

Benefits of different intensity of aerobic exercise in modulating body composition among obese young adults: a pilot randomized controlled trial

Research

Tinnitus functional index: validation of the German version for Switzerland

Research

Comparing five depression measures in depressed Chinese patients using item response theory: an examination of item properties, measurement precision and score comparability

Research

Health related quality of life in Dutch infants, toddlers, and young children